Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Protalix BioTherapeutics Q3 EPS $(0.04), Inline, Sales $10.35M Beat $10.00M Estimate

Author: Benzinga Newsdesk | November 06, 2023 07:51am
Protalix BioTherapeutics (AMEX:PLX) reported quarterly losses of $(0.04) per share which met the analyst consensus estimate. This is a 42.86 percent increase over losses of $(0.07) per share from the same period last year. The company reported quarterly sales of $10.35 million which beat the analyst consensus estimate of $10.00 million by 3.45 percent. This is a 27.06 percent decrease over sales of $14.18 million the same period last year.

Posted In: PLX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist